Cargando…

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside

SIMPLE SUMMARY: DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer (EOC) —especially the high-grade serous subtype—harbors a defect in at least one DNA damage response (DDR) pathway. Defective DDR results from a variety of lesions affecting homologous recombination (HR) and nonh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boussios, Stergios, Rassy, Elie, Moschetta, Michele, Ghose, Aruni, Adeleke, Sola, Sanchez, Elisabet, Sheriff, Matin, Chargari, Cyrus, Pavlidis, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405840/ https://www.ncbi.nlm.nih.gov/pubmed/36010882 http://dx.doi.org/10.3390/cancers14163888

Ejemplares similares

Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
por: Linares, Christian A., et al.
Publicado: (2023)

Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study
por: Vassiliou, Anna, et al.
Publicado: (2023)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
por: Ghose, Aruni, et al.
Publicado: (2021)

Wise Management of Ovarian Cancer: On the Cutting Edge
por: Boussios, Stergios, et al.
Publicado: (2020)

Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
por: Ghose, Aruni, et al.
Publicado: (2022)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities
por: Boussios, Stergios, et al.
Publicado: (2021)

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
por: Ioannidou, Evangelia, et al.
Publicado: (2021)

Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
por: Moschetta, Michele, et al.
Publicado: (2020)

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
por: Shah, Sidrah, et al.
Publicado: (2021)

Unraveling the Wide Spectrum of Melanoma Biomarkers
por: Revythis, Antonios, et al.
Publicado: (2021)

From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary
por: Mathew, Beatrice Gadiel, et al.
Publicado: (2023)

Aberrations of DNA Repair Pathways in Prostate Cancer—The State of the Art
por: Boussios, Stergios, et al.
Publicado: (2023)

A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives
por: Boussios, Stergios, et al.
Publicado: (2018)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
por: Shah, Sidrah, et al.
Publicado: (2022)

Exosomes in the Diagnosis and Treatment of Renal Cell Cancer
por: Boussios, Stergios, et al.
Publicado: (2023)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
por: Boussios, Stergios, et al.
Publicado: (2019)

Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered
por: Rassy, Elie, et al.
Publicado: (2020)

Ovarian cancer: state of the art and perspectives of clinical research
por: Boussios, Stergios, et al.
Publicado: (2020)

Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy
por: Ghose, Aruni, et al.
Publicado: (2022)

Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor
por: Boussios, Stergios, et al.
Publicado: (2015)

Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches
por: Uccello, Mario, et al.
Publicado: (2020)

Non-Epithelial Ovarian Cancers: How Much Do We Really Know?
por: Cheung, Alison, et al.
Publicado: (2022)

The Experience of a Single NHS England Trust on the Impact of the COVID-19 Pandemic on Junior and Middle-Grade Doctors: What Is Next?
por: Revythis, Antonios, et al.
Publicado: (2021)

COVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
por: Mahajan, Ishika, et al.
Publicado: (2022)

Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Bench and Bedside
por: Schmidt, Christian
Publicado: (2002)

From bench to bedside
por: Verdant, Colin L
Publicado: (2012)

The development of PARP inhibitors in ovarian cancer: from bench to bedside
por: Drew, Yvette
Publicado: (2015)

CAR-T cell therapy in ovarian cancer: from the bench to the bedside
por: Zhu, Xinxin, et al.
Publicado: (2017)

Surgery for T4 Colorectal Cancer in Older Patients: Determinants of Outcomes
por: Osseis, Michael, et al.
Publicado: (2022)

From Bench to Bedside: Immunotherapy for Prostate Cancer
por: Tse, Brian Wan-Chi, et al.
Publicado: (2014)

Sepsis: From Bench to Bedside
por: Silva, Eliézer, et al.
Publicado: (2008)

Sonochemotherapy: from bench to bedside
por: Lammertink, Bart H. A., et al.
Publicado: (2015)

Nutrition: From Bench to Bedside
por: Khan, Naim A., et al.
Publicado: (2016)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vi40eehv2862mlscme6p6ph4jh